This webinar will explore ways industry can help empower a stronger pathology-
driven approach, leading to better awareness of biomarker testing to inform 1L therapy selection in mCRC.

Hosted by the CAP Foundation and presented by Trent Coy, Diagnostics Solutions Director at Pfizer.

• Learn more about BRAF testing, understand the process turnaround
  time (TAT), and workflow efficiency.
• Gain insights on how you can raise awareness of biomarker testing to
  better inform 1L therapy selection in mCRC.
• Explore the challenges and opportunities faced in biomarker testing and
  therapy selection.

Presenter

Trent Coy
Diagnostics Solutions Director
Pfizer Oncology

As the Diagnostic Solutions Director (DSD) at Pfizer Oncology, Trent Coy is responsible for leading strategies and solutions that enable laboratories to perform optimal testing relative to precision medicine. As a certified Cytologist and Molecular Biology Technologist with 25 years of laboratory experience, Trent has implemented national AP programs and led national histology and cytology best practices teams, building on his extensive project and product management experience.